WO2007147868A3 - Prevention of muscle atrophy - Google Patents

Prevention of muscle atrophy Download PDF

Info

Publication number
WO2007147868A3
WO2007147868A3 PCT/EP2007/056181 EP2007056181W WO2007147868A3 WO 2007147868 A3 WO2007147868 A3 WO 2007147868A3 EP 2007056181 W EP2007056181 W EP 2007056181W WO 2007147868 A3 WO2007147868 A3 WO 2007147868A3
Authority
WO
WIPO (PCT)
Prior art keywords
muscle atrophy
prevention
treating muscle
relates
medicament
Prior art date
Application number
PCT/EP2007/056181
Other languages
French (fr)
Other versions
WO2007147868A2 (en
Inventor
Laurent Schaeffer
Francis Ramond
Saadi Khochbin
Original Assignee
Ens Ecole Normale Superieure D
Laurent Schaeffer
Francis Ramond
Saadi Khochbin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ens Ecole Normale Superieure D, Laurent Schaeffer, Francis Ramond, Saadi Khochbin filed Critical Ens Ecole Normale Superieure D
Publication of WO2007147868A2 publication Critical patent/WO2007147868A2/en
Publication of WO2007147868A3 publication Critical patent/WO2007147868A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method of treating muscle atrophy, a pathological condition associated with many diseases. The invention also relates to the use of an agent in the manufacture of a medicament for treating muscle atrophy. There is also provided a method of identifying agents for potential use in treating muscle atrophy.
PCT/EP2007/056181 2006-06-21 2007-06-21 Prevention of muscle atrophy WO2007147868A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0612273.3 2006-06-21
GB0612273A GB0612273D0 (en) 2006-06-21 2006-06-21 Prevention of muscle atrophy

Publications (2)

Publication Number Publication Date
WO2007147868A2 WO2007147868A2 (en) 2007-12-27
WO2007147868A3 true WO2007147868A3 (en) 2008-02-21

Family

ID=36803603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/056181 WO2007147868A2 (en) 2006-06-21 2007-06-21 Prevention of muscle atrophy

Country Status (2)

Country Link
GB (1) GB0612273D0 (en)
WO (1) WO2007147868A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100879A1 (en) 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
US20140147434A1 (en) * 2011-05-06 2014-05-29 Ecole Polytechnique Federale De Lausanne (Epfl) NCoR1 is a Physiological Modulator of Muscle Mass and Oxidative Function
KR102091037B1 (en) * 2013-11-20 2020-03-19 오하이오 스테이트 이노베이션 파운데이션 Hdac inhibitors for suppressing cancer-related cachexia
EP3071196B1 (en) * 2013-11-20 2019-03-27 Ohio State Innovation Foundation Hdac inhibitors for suppressing cancer-related cachexia
CN106929513A (en) * 2017-04-07 2017-07-07 东南大学 The nano antibody of mRNA codings and its application
JP2022552444A (en) 2019-09-27 2022-12-15 武田薬品工業株式会社 2-isoindole-1,3,4-oxadiazole derivatives useful as HDAC6 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018657A1 (en) * 2004-08-18 2006-02-23 University Of East Anglia Hdac inhibitors and methods of use thereof
US20060069049A1 (en) * 2003-12-29 2006-03-30 President And Fellows Of Harvard College Methods and reagents related to foxo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069049A1 (en) * 2003-12-29 2006-03-30 President And Fellows Of Harvard College Methods and reagents related to foxo
WO2006018657A1 (en) * 2004-08-18 2006-02-23 University Of East Anglia Hdac inhibitors and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLANCHARD F ET AL: "Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 10, no. 3, 1 February 2005 (2005-02-01), pages 197 - 204, XP004748155, ISSN: 1359-6446 *
GLOZAK ET AL: "Acetylation and deacetylation of non-histone proteins", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER, AMSTERDAM, NL, vol. 363, 19 December 2005 (2005-12-19), pages 15 - 23, XP005186882, ISSN: 0378-1119 *
HAGGARTY STEPHEN J ET AL: "Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 8, 15 April 2003 (2003-04-15), pages 4389 - 4394, XP002263858, ISSN: 0027-8424 *
HIRTZ D ET AL: "Challenges and opportunities in clinical trials for spinal muscular atrophy", NEUROLOGY, vol. 65, no. 9, November 2005 (2005-11-01), pages 1352 - 1357, XP002459627, ISSN: 0028-3878 *
KANDARIAN SUSAN C ET AL: "Intracellular signaling during skeletal muscle atrophy", MUSCLE & NERVE, vol. 33, no. 2, February 2006 (2006-02-01), pages 155 - 165, XP002459626, ISSN: 0148-639X *
SANDRI MARCO ET AL: "Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy", CELL, vol. 117, no. 3, 30 April 2004 (2004-04-30), pages 399 - 412, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
GB0612273D0 (en) 2006-08-02
WO2007147868A2 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
IL277322B (en) Compositions and methods for treating collagen-mediated diseases
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
WO2006078463A3 (en) Method for treating cardiovascular disease
WO2007022518A3 (en) New uses of glucoregulatory proteins
WO2007117971A3 (en) Ocular allergy treatments
WO2008012555A3 (en) Epitope reduction therapy
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008016659A3 (en) Agents for treating neurodegenerative diseases
EP2060264A4 (en) Agent for treating eye diseases
EP2139460A4 (en) Compositions and methods for the diagnosis, treatment, and prevention of amyotrophic lateral sclerosis and related neurological diseases
WO2007014943A3 (en) Therapy for neurological diseases
WO2007147868A3 (en) Prevention of muscle atrophy
WO2010077339A3 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2009074247A8 (en) Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
WO2007144057A3 (en) Antimicrobial carbon
WO2008067559A3 (en) Methods for treating and diagnosing fibrotic and fibroproliferative diseases
WO2008127279A3 (en) Methods for treating, preventing and diagnosing porcine ttv infection
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2006088786A3 (en) Compounds and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07765531

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07765531

Country of ref document: EP

Kind code of ref document: A2